Drawn from posts in the Medicine category, newest first. Each answer reads as a citable claim and links back to the source post for the trial data, the regulatory context, or the strategic argument.
The angle: medicine as a competitive industry shaped by patents, trial endpoints, and clinical translation, not as a public-relations narrative. The flagship coverage is the GLP-1 race between Novo Nordisk and Eli Lilly, where the entire $20B Ozempic franchise has to be replaced before the 2031 patent cliff.
Recurring questions: why oral semaglutide destroys 99% of its active ingredient before reaching the bloodstream, why Foundayo skips that problem entirely, why Novo lost 75% from June 2024 after CagriSema underperformed Zepbound head-to-head, what Amycretin’s 24.3% Phase 1 weight loss signals for the post-patent product map, how Isomorphic Labs’ IsoDDE benchmark scores against AlphaFold 3 on protein-ligand prediction.
The default move on this beat: find the constraint that closes off the easy story, then describe what’s actually happening inside it. Answers lead with the trial endpoint or the bioavailability number, not the press release.